Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2025 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Other Non-Current Liabilities of $400000.0 for Q1 2026, down 90.98% year-over-year from $4.4 million in Q1 2025, and down 90.98% quarter-over-quarter from $4.4 million in Q1 2025.
Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Other Non-Current Liabilities for 2 consecutive years, with $400000.0 the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2025 | 4.44 Mn |